Breast Biopsy Modified Radical Mastectomy with ER PR HER2/neu Analysis
Comprehensive Breast Cancer Diagnostic Testing
The Breast Biopsy Modified Radical Mastectomy with ER PR HER2/neu Analysis represents a sophisticated diagnostic approach in breast cancer management. This comprehensive testing protocol combines surgical tissue examination with advanced molecular biomarker analysis to provide crucial information for treatment planning and prognosis assessment. Following modified radical mastectomy surgery, the excised breast tissue undergoes detailed histopathological evaluation alongside specific receptor status determination.
What This Advanced Test Measures
This comprehensive diagnostic panel evaluates multiple critical biomarkers essential for breast cancer characterization:
- Estrogen Receptor (ER) Status: Determines if cancer cells have estrogen receptors, indicating potential responsiveness to hormone therapy
- Progesterone Receptor (PR) Status: Assesses progesterone receptor presence, providing additional hormonal therapy guidance
- HER2/neu Protein Expression: Evaluates human epidermal growth factor receptor 2 levels, crucial for targeted therapy decisions
- Tissue Architecture: Examines cancer cell morphology, grade, and invasion patterns
- Surgical Margin Assessment: Confirms complete tumor removal and evaluates resection boundaries
Who Should Consider This Comprehensive Testing
This advanced diagnostic procedure is specifically indicated for patients who have undergone modified radical mastectomy for breast cancer management. The test is particularly valuable for:
- Patients diagnosed with invasive breast cancer requiring comprehensive biomarker profiling
- Individuals with newly diagnosed breast cancer undergoing surgical intervention
- Patients where hormone receptor status and HER2 status will influence treatment selection
- Cases requiring confirmation of complete tumor excision with clear surgical margins
- Patients who may benefit from targeted therapy or hormonal treatment approaches
Clinical Indications and Symptoms
This testing is typically performed following the identification of breast abnormalities through:
- Palpable breast masses or lumps detected during clinical examination
- Suspicious findings on mammography or breast ultrasound imaging
- Abnormal breast changes including skin dimpling, nipple retraction, or discharge
- Previous biopsy confirmation of breast malignancy requiring definitive surgical management
Significant Benefits of Comprehensive Breast Cancer Analysis
Undergoing this detailed diagnostic evaluation provides multiple advantages for breast cancer patients:
- Personalized Treatment Planning: Enables tailored therapy selection based on individual biomarker profiles
- Targeted Therapy Guidance: Identifies patients who may benefit from specific biological agents
- Prognostic Information: Provides valuable insights into disease behavior and potential outcomes
- Surgical Confirmation: Verifies complete tumor removal and assesses resection adequacy
- Treatment Response Prediction: Helps anticipate effectiveness of various therapeutic approaches
- Comprehensive Cancer Characterization: Offers complete pathological assessment for optimal management
Understanding Your Test Results
Your comprehensive breast cancer analysis report will include detailed information about:
- ER/PR Status: Positive results indicate hormone receptor expression, suggesting potential responsiveness to hormonal therapies like tamoxifen or aromatase inhibitors
- HER2/neu Status: Positive findings may indicate eligibility for targeted therapies such as trastuzumab (Herceptin)
- Tumor Grade and Stage: Provides information about cancer aggressiveness and extent
- Surgical Margin Status: Confirms whether cancer cells are present at the edge of removed tissue
- Lymph Node Involvement: Assesses cancer spread to regional lymph nodes when included in mastectomy
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Breast Biopsy Modified Radical Mastectomy with ER PR HER2/neu Analysis | $276 (Regular Price) |
| Discounted Price | $206 |
Nationwide Testing Accessibility
GGC DNA maintains comprehensive testing facilities across major metropolitan areas throughout the United States. Our advanced diagnostic services are available in:
- New York Metropolitan Area: State-of-the-art pathology laboratories serving the Northeast region
- Los Angeles and Southern California: Advanced cancer diagnostic centers with rapid turnaround
- Chicago and Midwest Region: Comprehensive breast cancer testing facilities
- Houston and Texas Area: Specialized oncology pathology services
- Phoenix and Southwest: Modern diagnostic laboratories with expert pathologists
Take Control of Your Breast Health Today
Comprehensive breast cancer analysis provides essential information for making informed treatment decisions. Our advanced testing combines traditional histopathology with modern biomarker analysis to deliver complete diagnostic insights. With a turnaround time of just 6 days, you can receive critical information promptly to guide your healthcare journey.
Ready to schedule your comprehensive breast cancer analysis? Contact our dedicated patient care team at +1(267) 388-9828 to book your test or discuss your diagnostic needs. Our experienced healthcare professionals are available to answer your questions and facilitate seamless testing coordination.
Note: This test requires tissue samples preserved in 10% Neutral Buffered Formalin and is typically performed following modified radical mastectomy procedures. A doctor’s prescription is generally required, though exceptions apply for surgical cases, pregnancy-related testing, and international travel preparations.
